View source for Belantamab mafodotin-blmf

'''Belantamab mafodotin-blmf''' (pronunciation: bel-an-TAM-ab maf-oh-DOH-tin) is a [[monoclonal antibody]]-[[drug conjugate]] used for the treatment of [[multiple myeloma]]. It is marketed under the brand name Blenrep by [[GlaxoSmithKline]].

==Etymology==
The name "Belantamab mafodotin-blmf" is derived from its components: "Bel" for the monoclonal antibody belantamab, "maf" for the drug mafodotin, and "blmf" as a unique identifier.

==Usage==
Belantamab mafodotin-blmf is used for the treatment of adults with relapsed or refractory multiple myeloma who have received at least four prior therapies including an [[anti-CD38 monoclonal antibody]], a [[proteasome inhibitor]], and an [[immunomodulatory agent]].

==Mechanism of Action==
Belantamab mafodotin-blmf works by binding to the [[BCMA (B-cell maturation antigen)]] on the surface of multiple myeloma cells, and delivering the cytotoxic drug mafodotin directly to the cells.

==Side Effects==
Common side effects of Belantamab mafodotin-blmf include [[keratopathy]], blurred vision, dry eyes, and decreased visual acuity. 

==Related Terms==
* [[Monoclonal antibody]]
* [[Drug conjugate]]
* [[Multiple myeloma]]
* [[BCMA (B-cell maturation antigen)]]
* [[Anti-CD38 monoclonal antibody]]
* [[Proteasome inhibitor]]
* [[Immunomodulatory agent]]
* [[Keratopathy]]

[[Category:Medicine]]
[[Category:Pharmacology]]
[[Category:Oncology]]

{{dictionary-stub}}